Intensive Care Medicine

, Volume 32, Issue 8, pp 1248–1251 | Cite as

Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome

  • Hendrik Schmidt
  • Ralf Hennen
  • Alexander Keller
  • Martin Russ
  • Ursula Müller-Werdan
  • Karl Werdan
  • Michael Buerke
Brief Report

Abstract

Objective

The multiple organ dysfunction syndrome (MODS) is the sequential failure of several organ systems after a trigger event, such as sepsis, pneumonia or cardiogenic shock. Even today, mortality is high. Statin therapy is associated with reduction of inflammation and subsequent rates of severe sepsis and ICU admission of patients admitted to hospital with presumed or documented acute bacterial infection. Our study aimed to characterize a potential survival benefit by statin therapy in MODS patients.

Design

Retrospective cohort study.

Setting

Twelve-bed medical intensive care unit in a university center.

Patients

Forty score-defined MODS patients under statin treatment and 80 age- and sex-matched score-defined MODS patients without statin treatment. Inclusion criterion was an APACHE II score ≥ 20 at admission to ICU.

Interventions

Assessment of statin treatment and calculation of disease severity by scoring. The patients were followed up for 28-day mortality as well as for hospital mortality.

Measurements and results

The MODS severity was equally pronounced in both groups. There were 42/80 deaths in the group without statin treatment and 13/40 deaths in the statin group (28-day mortality 53% vs. 33%, p = 0.03). Cox proportional hazard analysis revealed a hazard ratio of 0.53 (95% CI 0.29–0.99, p = 0.04). Hospital mortality was calculated at 72% (non-statin group) vs. 35% (statin group; chi-square  = 15.6, p < 0.0001). The overall hospital mortality was 60%.

Conclusions

Patients under statin treatment developing MODS might have a better outcome than patients without statin therapy, probably by reduction of inflammatory responses and increase of vagal activity in MODS.

Keywords

Multiple organ dysfunction syndrome APACHE II score Sepsis Statin therapy 

Notes

Acknowledgements

We are indebted to D. Moenning and P. Tymiec for their valuable contributions in collecting data and for technical assistance.

References

  1. 1.
    Mekontso-Dessap A, Brun-Buisson C (2006) Statins: the next step in adjuvant therapy for sepsis? Intensive Care Med 32:11–14PubMedCrossRefGoogle Scholar
  2. 2.
    Merx MW, Weber C (2005) Statins: a preventive strike against sepsis in patients with cardiovascular disease? Lancet DOI: 10.1016/S0140–6736(06)Google Scholar
  3. 3.
    Warnholtz A, Genth-Zotz S, Münzel T (2005) Should treatment of sepsis include statins? Circulation 111:1735–1737PubMedCrossRefGoogle Scholar
  4. 4.
    Moerer O, Schmid A, Hofmann M, Herklotz A, Reinhart K, Werdan K, Schneider H, Burchardi H (2000) Direct costs of severe sepsis in three German intensive care units based on retrospective electronic patient record analysis of resource use. Intensive Care Med 28:1440–1446CrossRefGoogle Scholar
  5. 5.
    Pruefer D, Makowski J, Schnell M, Buerke U, Dahm M, Oelert H, Sibelius U, Grandel U, Grimminger F, Seeger W, Meyer J, Darius H, Buerke M (2002) Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin. Circulation 106:2104–2110PubMedCrossRefGoogle Scholar
  6. 6.
    Merx MW, Liehn EA; Janssens U, Lütticken R, Schrader J, Hanrath P, Weber C (2004) HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 109:2560–2565PubMedCrossRefGoogle Scholar
  7. 7.
    Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, Friger M, Zeller L, Danon A (2004) Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 110:880–885PubMedCrossRefGoogle Scholar
  8. 8.
    Kruger P, Fitzsimmons K, Cook D, Jones M, Nimmo G (2006) Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med 32:75–79PubMedCrossRefGoogle Scholar
  9. 9.
    Schmidt H, Hennen R, Keller A, Rauchhaus M, Russ M, Mueller-Werdan U, Werdan K, Buerke M (2005) Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome. Intensive Care Med 31 [Suppl 1]: A10Google Scholar
  10. 10.
    Schmidt H, Müller-Werdan U, Hoffmann T, Francis DP, Piepoli MF, Rauchhaus M, Prondzinsky R, Loppnow H, Buerke M, Hoyer D, Werdan K (2005) Autonomic dysfunction predicts mortality in patients with multiple organ dysfunction syndrome of different age groups. Crit Care Med 33:1994–2002PubMedCrossRefGoogle Scholar
  11. 11.
    Schmidt H, Müller-Werdan U, Nuding S, Hoffmann T, Francis DP, Hoyer D, Rauchhaus M, Werdan K (2004) Impaired chemoreflex sensitivity in adult patients with multiple organ dysfunction syndrome – the potential role of disease severity. Intensive Care Med 30:665–672PubMedCrossRefGoogle Scholar
  12. 12.
    Hackam DG,Mamdani M, Li P, Redelmeier DA (2006) Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 367:413–418PubMedCrossRefGoogle Scholar
  13. 13.
    Liappis AP, Kan VL, Rochester CG, Simon GL (2001) The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 33:1352–1357PubMedCrossRefGoogle Scholar
  14. 14.
    Fernandez R, De Pedro VJ, Artigas A (2006) Statin therapy prior to ICU admission: protection against infection or a severity marker? Intensive Care Med 32:160–164PubMedCrossRefGoogle Scholar
  15. 15.
    Steiner S, Speidl WS, Pleiner J, Seidinger D, Zorn G, Kaun C, Wojta J, Huber K, Minar E, Wolzt M, Kopp CW (2005) Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 111:1841–1846PubMedCrossRefGoogle Scholar
  16. 16.
    Tracey KJ (2002) The inflammatory reflex. Nature 420:853–859PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Hendrik Schmidt
    • 1
  • Ralf Hennen
    • 1
  • Alexander Keller
    • 1
  • Martin Russ
    • 1
  • Ursula Müller-Werdan
    • 1
  • Karl Werdan
    • 1
  • Michael Buerke
    • 1
  1. 1.Department of Medicine IIIMartin Luther University Halle-Wittenberg, Klinikum KröllwitzHalle/SaaleGermany

Personalised recommendations